Myanmar Pharmaceutical Factory YangonYangon Myanmar Pharmaceutical Plant
Myanma Pharmaceutical Industrial Enterprise monitors and manages the following plants, equine and ovine farms and plantations for pharmaceutical manufacture and technological advancement.
P.P/ Kraft paper laminated cement bags.
Ongoing BPI opens third facility to increase performance
DrAung Zaw, Deputy General Director of the Pharmaceutical Factory (Insein), Ministry of Industry, said the third and new BPI facility, which will manufacture pellets and capsule, will go into operation in July. "We launched a new modernization of the factory to boost the manufacture of pharmaceuticals. He said yesterday: "The new facility will manufacture birth control drugs, pellets and capsule.
The Myanmar Pharmaceutical Factory (Insein) will increase manufacturing of Myanmar's pharmaceuticals to K 36.321 billion in 2017-2018, one civil servant said. Myanmar Pharmaceutical Factory, known as Burma Pharmaceutical Industry (BPI), is a state-owned factory under the Ministry of Industry. Pharmafabrik Insein produces more than 180 medicinal devices under the "BPI" name.
Insein pharmaceutical factory is being updated to meet global benchmarks and a regulatory spending target with Good Manufacturing Product Standards Myanmar compliant product. The facility will manufacture approximately 4 million injections. "We are trying to make six new drug lines this year. The BPI delivers medicinal devices to the Ministry of Defence, the Ministry of Health and Sports and the general population.
Government company wants to stimulate pharmaceutical manufacturing in 2018
Myanmar Pharmaceutical Industrial Enterprise (MPIE) is aiming to boost drug manufacture next year following the construction of new facilities at the Insein plant, a high-ranking MPIE officer said. MPIE CEO U Ko Ko Ko Aung said the firm hoped to manufacture K50 billion (US$36.65 million) of drugs this year, which is more than last year's K30 billion.
"Since the new Myanmar Pharmaceutical Factory (MPF) facilities have been put into operation this year, we want to expand our manufacturing capability next year from what we have been producing this year," he said on Sunday. This year, eight types of new medicines were made at the Insein Pharmaceutical Factory, he added.
The Myanmar Pharmaceutical Factory in Insein currently manufactures 180 types of drugs, which include powder, fluids, capsules and pills. MPF, formerly known as Burma Pharmaceutical Industry or BPI, is a state-owned company under the Ministry of Industry. This new MPF program, which has been in operation since 2013 and reached its peak this year, concentrated on modernizing the plants at the MPF factory in Insein.
In all, K 64.6 billion was provided for the modernisation to make sure that the production plant meets good production practice and meets internationally accepted quality control requirements. It involved the building of new premises and production lines with state-of-the-art technology. New installations comprise antibiotic production lines, vaccine production, serpent anti-venoma, pills and capsule production and a storage site, all of which were put into operation last year.
"We are not only trying to boost production, but also to manufacture new types of drugs. Said they were planning to be exporting Serpent Anti-Venom to Laos and Cambodia next year. BPI's principal purchaser of Anti-Venom is the Ministry of Health and Sports, which purchased approximately 80,000 tins of Anti-Venom.
The MPF product range is mainly distributed by the Ministry of Health and Sport and the Ministry of Defence. Mr U Ko Ko Ko Aung added that the old facilities will be modernised next year in collaboration with the business community. "Three privately owned businesses were chosen to modernize the old facility and construct the Insein factory to work with us," he said.
MPlE currently manufactures between 10 and 15 per cent of the drugs required by the state. Other pharmaceutical products are exported from China, India, Thailand and other parts of the world. "There are 45 drugs from India that are mainly exported to the domestic healthcare market," said Dr. Win Si Thu, Ph. D., President of the Myanmar Pharmaceutical and Medial Equipment Entrepreneurs' Association.
"He said the Chinese authorities are promoting the production of drugs on the ground because they are interested in improving the country's pharmaceutical industries.